The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) (XABG-FIH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04545112
Recruitment Status : Enrolling by invitation
First Posted : September 10, 2020
Last Update Posted : January 26, 2023
Information provided by (Responsible Party):

Brief Summary:
A FIH study to collect preliminary device safety, feasibility and performance data of the XABG in patients with symptomatic coronary artery disease (SCAD), with suitable multi vessel disease (MVD) and selected by the local Heart Team for elective coronary artery bypass grafts surgery of at least 3 bypass grafts (minimally 1 artery and 2 veins or 2 arteries and 1 vein).

Condition or disease Intervention/treatment Phase
Multi Vessel Coronary Artery Disease Device: CABG Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG)
Actual Study Start Date : October 22, 2020
Estimated Primary Completion Date : March 15, 2026
Estimated Study Completion Date : March 15, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: XABG Device: CABG
Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.

Primary Outcome Measures :
  1. Procedural success during the first 30 days [ Time Frame: 30 days ]
    XABG technology performs as intended with successful proximal and distal anastomoses and graft patency at the conclusion of the procedure and at 30 days. Patency is defined as a diameter stenosis less than 50%

  2. Freedom from device related Serious Adverse Events (SAEs) [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Intimal hyperplasia area [ Time Frame: 12 months ]
    Assessed by OCT

  2. Graft patency [ Time Frame: 30 days, 6 months, 12 months ]
    Patency defined as a diameter stenosis less than 50%

  3. Lumen diameter uniformity [ Time Frame: 30 days, 6 months, 12 months ]
    Using Fitzgibbon's 3-point ordinal uniformity scale

  4. Freedom from Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: 30 days, 6 months, 12 months, and yearly until 5 years ]
    Absence of device related SAEs

  5. Freedom from vein harvesting related wound infection, non-infective wound healing disturbances, and leg pain [ Time Frame: 30 days and 6 months ]
    Leg pain will be assessed by standard 10-point VAS scale and presented as descriptive statistics

  6. Composite of all causes of mortality - (cerebrovascular stroke, myocardial infarction, re-operation, or intervention) [ Time Frame: 5 years ]
    Assessed for XABG and Saphenous vein graft (SVG) separately

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All gender, 19 years of age or older with a minimum life expectancy of 2 years
  • Elective patient, selected and accepted by the local Heart Team and confirmed by the Screening Committee for an on-pump full sternotomy CABG surgery
  • IMA conduit indicated and feasible for the LAD, SVG CABG indicated and feasible for the circumflex artery (LCX) and right coronary artery (RCA) territories
  • Native coronary vessels with proximal occlusion and/or critical stenosis. XABG target vessel with a diameter of ≥ 2 mm and sufficient distal run-off (thrombolysis in myocardial infarction risk (TIMI)-Score ≥ 2).
  • Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
  • Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up CT/MRI scan and coronary angiogram
  • Patient is suitable for percutaneous coronary intervention (PCI) procedures in case of required emergent procedures at discretion of the local Heart Team

Exclusion Criteria:

  • Any previous open-heart surgery or surgical/transcatheter procedure resulting in complex CABG surgery and/or suboptimal cardiovascular imaging of the chest
  • History of cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation
  • Concomitant cardiac surgery (e.g. valve treatment, ablation)
  • No or insufficient intrathoracic arteries and/or saphenous veins available to undergo full CABG procedure (i.e. treat all target vessels)
  • Myocardial infarction (MI) within 21 days or cerebral vascular accident (CVA) within 90 days prior to the CABG procedure
  • Left ventricular ejection fraction ≤ 35%
  • Severe kidney disease, renal dysfunction (Cr> 2.0mg/dL) or Glomerular Filtration Rate (GFR) < 50mL/min or active dialysis patients
  • Moderate to severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume (FEV) <1.5 lit/sec
  • Endocarditis, pericarditis, or any other active systemic infection that would interfere with subject safety
  • Active bleeding disorder and/or any coagulopathy or thromboembolic disease or other indication requiring anticoagulation
  • Known Heparin Induced Thrombocytopenia (HIT)
  • Abnormal blood values (e.g. leukopenia, anemia or thrombocytopenia) that could influence graft hemostasis or patient recovery.
  • Condition requiring immunosuppressive therapy or any chronic inflammatory/autoimmune disease or medication that likely interferes with restorative therapies
  • Allergies to study device (Nitinol) or agents/medication, such as contrast agents, antiplatelet therapy, beta-blocker, statins required for study assessment or optimal post-CABG medical treatment (hospital SOC)
  • Need for emergency surgery for any reason and/or intervention/surgery prior to and within 12 months after the CABG surgery that requires antiplatelet therapy discontinuation
  • Currently in investigational device or drug study or participated in the last 30 days
  • Pregnancy or females currently lactating or of childbearing potential who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
  • Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance
  • Has any other condition, in the opinion of the principal investigator, which would put the patient at increased risk from participating in the study or otherwise prevent participation

Intra-operative exclusion criteria:

  • Severe calcified aorta (porcelain aorta) or diseased aorta that precludes proximal vein graft anastomoses
  • No or insufficient intrathoracic artery and/or saphenous veins available to undergo full CABG procedure (i.e. treat all target vessels).
  • Unsuccessful IMA anastomosis
  • After chest opening and visual inspection identification of active pericarditis/endocarditis and/or diffuse calcification in target vessels and/or any other reason precluding sufficient distal XABG and/or SVG anastomoses.
  • Smaller distal coronary artery and/or poor distal run-off as initially expected based on the coronary angiogram.
  • Hemodynamic instability before XABG attempt

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04545112

Layout table for location information
UZ Leuven
Leuven, Belgium
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Bart Meuris, MD UZ Leuven
Layout table for additonal information
Responsible Party: Xeltis Identifier: NCT04545112    
Other Study ID Numbers: XEL-CR-07
First Posted: September 10, 2020    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases